OA11276A - Novel composition comprising an ssri and a beta-b locker. - Google Patents

Novel composition comprising an ssri and a beta-b locker. Download PDF

Info

Publication number: OA11276A
Authority: OA; OAPI
Prior art keywords: pharmaceutical composition; composition according; blocker; dépréssion; release
Prior art date: 1997-07-11

Application number

OA1200000006A

Other languages

English (en)

Inventor

Paul John Cummings

Ian Frederic Tulloch

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-11

Filing date

2000-01-11

Publication date

2003-07-31

2000-01-11 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-07-31 Publication of OA11276A publication Critical patent/OA11276A/en

Links

239000000203 mixture Substances 0.000 title claims description 27
239000002876 beta blocker Substances 0.000 claims abstract description 22
229940097320 beta blocking agent Drugs 0.000 claims abstract description 22
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract description 21
239000012730 sustained-release form Substances 0.000 claims abstract description 20
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract 13
229960002508 pindolol Drugs 0.000 claims description 22
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical group CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 21
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 19
238000009472 formulation Methods 0.000 claims description 15
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 13
229960002296 paroxetine Drugs 0.000 claims description 13
238000013268 sustained release Methods 0.000 claims description 12
206010036618 Premenstrual syndrome Diseases 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 7
208000007848 Alcoholism Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
208000032841 Bulimia Diseases 0.000 claims description 4
206010006550 Bulimia nervosa Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
206010041250 Social phobia Diseases 0.000 claims description 4
201000007930 alcohol dependence Diseases 0.000 claims description 4
208000022531 anorexia Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
206010061428 decreased appetite Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
208000024732 dysthymic disease Diseases 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
208000019906 panic disease Diseases 0.000 claims description 4
208000002271 trichotillomania Diseases 0.000 claims description 4
208000000094 Chronic Pain Diseases 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
201000009032 substance abuse Diseases 0.000 claims 2
231100000736 substance abuse Toxicity 0.000 claims 2
208000011117 substance-related disease Diseases 0.000 claims 2
230000001684 chronic effect Effects 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 description 10
239000002775 capsule Substances 0.000 description 8
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229960005183 paroxetine hydrochloride Drugs 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 2
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
229920003084 Avicel® PH-102 Polymers 0.000 description 2
229920003094 Methocel™ K4M Polymers 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229960004038 fluvoxamine Drugs 0.000 description 2
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
229940049654 glyceryl behenate Drugs 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000009478 high shear granulation Methods 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960002035 penbutolol Drugs 0.000 description 1
KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

OA1200000006A 1997-07-11 2000-01-11 Novel composition comprising an ssri and a beta-b locker. OA11276A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9714675.7A GB9714675D0 (en)	1997-07-11	1997-07-11	Novel composition

Publications (1)

Publication Number	Publication Date
OA11276A true OA11276A (en)	2003-07-31

Family

ID=10815744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000006A OA11276A (en)	1997-07-11	2000-01-11	Novel composition comprising an ssri and a beta-b locker.

Country Status (26)

Country	Link
EP (1)	EP0996466A2 (id)
JP (1)	JP2002508003A (id)
KR (1)	KR20010021644A (id)
CN (1)	CN1262627A (id)
AP (1)	AP2000001728A0 (id)
AR (1)	AR016128A1 (id)
AU (1)	AU9340198A (id)
BG (1)	BG104119A (id)
BR (1)	BR9810996A (id)
CA (1)	CA2295822A1 (id)
CO (1)	CO4950552A1 (id)
DZ (1)	DZ2556A1 (id)
EA (1)	EA200000112A1 (id)
GB (1)	GB9714675D0 (id)
HU (1)	HUP0003074A3 (id)
ID (1)	ID24191A (id)
IL (1)	IL133869A0 (id)
MA (1)	MA24604A1 (id)
NO (1)	NO20000107D0 (id)
OA (1)	OA11276A (id)
PE (1)	PE99699A1 (id)
PL (1)	PL338017A1 (id)
SK (1)	SK72000A3 (id)
TR (1)	TR200000074T2 (id)
WO (1)	WO1999002142A2 (id)
ZA (1)	ZA986138B (id)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE457169T1 (de)	1998-10-15	2010-02-15	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
CA2348871C (en)	1998-11-02	2009-04-14	John G. Devane	Multiparticulate modified release composition
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
GB0004003D0 (en) *	2000-02-22	2000-04-12	Knoll Ag	Therapeutic agents
EP2283829A1 (en)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Controlled release hydrocodone formulations
EP1793818A2 (en) *	2004-09-17	2007-06-13	Neurocure Ltd.	Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) *	2006-09-08	2009-03-18	山东益康药业有限公司	复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2732335C2 (de) *	1976-07-27	1983-01-20	Sandoz-Patent-GmbH, 7850 Lörrach	Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
WO1997006792A1 (en) *	1995-08-16	1997-02-27	Eli Lilly And Company	Potentiation of serotonin response
EP0792649A1 (en) *	1996-02-29	1997-09-03	Eli Lilly And Company	Treatment of sleep disorders

1997
- 1997-07-11 GB GBGB9714675.7A patent/GB9714675D0/en active Pending
1998
- 1998-07-07 BR BR9810996-0A patent/BR9810996A/pt not_active Application Discontinuation
- 1998-07-07 TR TR2000/00074T patent/TR200000074T2/xx unknown
- 1998-07-07 JP JP50818599A patent/JP2002508003A/ja active Pending
- 1998-07-07 PL PL98338017A patent/PL338017A1/xx unknown
- 1998-07-07 EP EP98946294A patent/EP0996466A2/en not_active Withdrawn
- 1998-07-07 CN CN98806975A patent/CN1262627A/zh active Pending
- 1998-07-07 AP APAP/P/1999/001728A patent/AP2000001728A0/en unknown
- 1998-07-07 KR KR1020007000202A patent/KR20010021644A/ko not_active Withdrawn
- 1998-07-07 WO PCT/EP1998/004971 patent/WO1999002142A2/en not_active Ceased
- 1998-07-07 EA EA200000112A patent/EA200000112A1/ru unknown
- 1998-07-07 AU AU93401/98A patent/AU9340198A/en not_active Abandoned
- 1998-07-07 SK SK7-2000A patent/SK72000A3/sk unknown
- 1998-07-07 HU HU0003074A patent/HUP0003074A3/hu unknown
- 1998-07-07 ID IDW20000035A patent/ID24191A/id unknown
- 1998-07-07 IL IL13386998A patent/IL133869A0/xx unknown
- 1998-07-07 CA CA002295822A patent/CA2295822A1/en not_active Abandoned
- 1998-07-08 DZ DZ980166A patent/DZ2556A1/xx active
- 1998-07-10 AR ARP980103371A patent/AR016128A1/es unknown
- 1998-07-10 PE PE1998000612A patent/PE99699A1/es not_active Application Discontinuation
- 1998-07-10 CO CO98039260A patent/CO4950552A1/es unknown
- 1998-07-10 MA MA25165A patent/MA24604A1/fr unknown
- 1998-07-10 ZA ZA9806138A patent/ZA986138B/xx unknown
2000
- 2000-01-10 NO NO20000107A patent/NO20000107D0/no not_active Application Discontinuation
- 2000-01-11 OA OA1200000006A patent/OA11276A/en unknown
- 2000-02-01 BG BG104119A patent/BG104119A/xx unknown

Also Published As

Publication number	Publication date
PL338017A1 (en)	2000-09-25
PE99699A1 (es)	1999-12-21
DZ2556A1 (fr)	2003-02-15
NO20000107L (no)	2000-01-10
EP0996466A2 (en)	2000-05-03
WO1999002142A3 (en)	1999-04-15
EA200000112A1 (ru)	2000-10-30
CA2295822A1 (en)	1999-01-21
CO4950552A1 (es)	2000-09-01
HUP0003074A3 (en)	2001-12-28
ID24191A (id)	2000-07-13
TR200000074T2 (tr)	2000-05-22
MA24604A1 (fr)	1999-04-01
IL133869A0 (en)	2001-04-30
AR016128A1 (es)	2001-06-20
SK72000A3 (en)	2000-12-11
AP2000001728A0 (en)	2000-03-31
BG104119A (en)	2000-12-29
HUP0003074A2 (hu)	2001-01-29
ZA986138B (en)	2000-01-10
NO20000107D0 (no)	2000-01-10
KR20010021644A (ko)	2001-03-15
BR9810996A (pt)	2000-08-08
AU9340198A (en)	1999-02-08
GB9714675D0 (en)	1997-09-17
WO1999002142A2 (en)	1999-01-21
JP2002508003A (ja)	2002-03-12
CN1262627A (zh)	2000-08-09

Publication	Publication Date	Title
KR101234940B1 (ko)	2013-02-19	안정한 서방출형의 경구 투여용 조성물
KR101890450B1 (ko)	2018-08-21	Ｃｎｓ 장애의 치료에 사용되는 브렉스피프라졸 또는 이의 염 및 2 차 약물을 포함하는 조합물
CA2182004C (en)	2000-10-31	Film coated tablet of paracetamol and domperidone
EP2591773A2 (en)	2013-05-15	Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
US20120064133A1 (en)	2012-03-15	Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
EA023807B1 (ru)	2016-07-29	Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA014294B1 (ru)	2010-10-29	Комбинация снотворного агента длительного действия и снотворного агента короткого действия
MXPA00012957A (es)	2003-06-19	Composicion para dosis oral de liberacion extendida.
TW200900094A (en)	2009-01-01	Solid preparation
HUP0402104A2 (hu)	2005-03-29	3-(3-Dimetilamino-1-etil-2-metil-propil)-fenolt tartalmazó, késleltetett hatóanyag-leadású gyógyszer
US20120202820A1 (en)	2012-08-09	Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin
WO2010128525A2 (en)	2010-11-11	A formulation of ivabradine for treating the cardiovascular disease
JP2004502734A (ja)	2004-01-29	一酸化窒素シンターゼ活性の増強方法
IL149496A (en)	2009-12-24	Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
JP2004502729A (ja)	2004-01-29	Ｓｓｒｉおよびエストロゲン剤の組み合わせ
CN112618505B (zh)	2022-11-15	一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法
JP2016512234A (ja)	2016-04-25	薬学的複合製剤
CA2295822A1 (en)	1999-01-21	Novel composition
WO2014014129A1 (en)	2014-01-23	Solid preparation
JP7558593B2 (ja)	2024-10-01	イブプロフェン制御放出錠及びその調製方法
US7767227B2 (en)	2010-08-03	Galenical form for oral administration with prolonged release of molsidomine
CN101330913A (zh)	2008-12-24	依他普仑的修饰和脉冲释放药物制剂
CN101756977A (zh)	2010-06-30	阿折地平的缓释制剂及其制备方法
TW201626990A (zh)	2016-08-01	含有褪黑激素和舍曲林的口服複合錠劑
KR101310099B1 (ko)	2013-09-23	아세클로페낙 함유 방출제어형 정제